-
Something wrong with this record ?
Design, Synthesis and Antimicrobial Evaluation of New N-(1-Hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)(hetero)aryl-2-carboxamides as Potential Inhibitors of Mycobacterial Leucyl-tRNA Synthetase
P. Šlechta, AA. Needle, O. Jand'ourek, P. Paterová, K. Konečná, P. Bárta, J. Kuneš, V. Kubíček, M. Doležal, M. Kučerová-Chlupáčová
Language English Country Switzerland
Document type Journal Article
NLK
Free Medical Journals
from 2000
Freely Accessible Science Journals
from 2000
PubMed Central
from 2007
Europe PubMed Central
from 2007
ProQuest Central
from 2000-03-01
Open Access Digital Library
from 2000-01-01
Open Access Digital Library
from 2007-01-01
Health & Medicine (ProQuest)
from 2000-03-01
ROAD: Directory of Open Access Scholarly Resources
from 2000
PubMed
36769275
DOI
10.3390/ijms24032951
Knihovny.cz E-resources
- MeSH
- Amides chemistry pharmacology MeSH
- Amino Acyl-tRNA Synthetases * MeSH
- Anti-Bacterial Agents pharmacology MeSH
- Anti-Infective Agents * pharmacology MeSH
- Antitubercular Agents pharmacology MeSH
- Fungi MeSH
- Humans MeSH
- Microbial Sensitivity Tests MeSH
- Mycobacterium tuberculosis * MeSH
- Molecular Docking Simulation MeSH
- Structure-Activity Relationship MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
Tuberculosis remains a serious killer among infectious diseases due to its incidence, mortality, and occurrence of resistant mycobacterial strains. The challenge to discover new antimycobacterial agents forced us to prepare a series of N-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)(hetero)aryl-2-carboxamides 1-19 via the acylation of 6-aminobenzo[c][1,2]oxaborol-1(3H)-ol with various activated (hetero)arylcarboxylic acids. These novel compounds have been tested in vitro against a panel of clinically important fungi and bacteria, including mycobacteria. Some of the compounds inhibited the growth of mycobacteria in the range of micromolar concentrations and retained this activity also against multidrug-resistant clinical isolates. Half the maximal inhibitory concentrations against the HepG2 cell line indicated an acceptable toxicological profile. No growth inhibition of other bacteria and fungi demonstrated selectivity of the compounds against mycobacteria. The structure-activity relationships have been derived and supported with a molecular docking study, which confirmed a selectivity toward the potential target leucyl-tRNA synthetase without an impact on the human enzyme. The presented compounds can become important materials in antimycobacterial research.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23004260
- 003
- CZ-PrNML
- 005
- 20250305132156.0
- 007
- ta
- 008
- 230418s2023 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/ijms24032951 $2 doi
- 035 __
- $a (PubMed)36769275
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Šlechta, Petr $u Department of Pharmaceutical Chemistry and Pharmaceutical Analysis, Faculty of Pharmacy in Hradec Králové, Charles University, 500 05 Hradec Králové, Czech Republic $1 https://orcid.org/0000000278149353 $7 xx0329837
- 245 10
- $a Design, Synthesis and Antimicrobial Evaluation of New N-(1-Hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)(hetero)aryl-2-carboxamides as Potential Inhibitors of Mycobacterial Leucyl-tRNA Synthetase / $c P. Šlechta, AA. Needle, O. Jand'ourek, P. Paterová, K. Konečná, P. Bárta, J. Kuneš, V. Kubíček, M. Doležal, M. Kučerová-Chlupáčová
- 520 9_
- $a Tuberculosis remains a serious killer among infectious diseases due to its incidence, mortality, and occurrence of resistant mycobacterial strains. The challenge to discover new antimycobacterial agents forced us to prepare a series of N-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)(hetero)aryl-2-carboxamides 1-19 via the acylation of 6-aminobenzo[c][1,2]oxaborol-1(3H)-ol with various activated (hetero)arylcarboxylic acids. These novel compounds have been tested in vitro against a panel of clinically important fungi and bacteria, including mycobacteria. Some of the compounds inhibited the growth of mycobacteria in the range of micromolar concentrations and retained this activity also against multidrug-resistant clinical isolates. Half the maximal inhibitory concentrations against the HepG2 cell line indicated an acceptable toxicological profile. No growth inhibition of other bacteria and fungi demonstrated selectivity of the compounds against mycobacteria. The structure-activity relationships have been derived and supported with a molecular docking study, which confirmed a selectivity toward the potential target leucyl-tRNA synthetase without an impact on the human enzyme. The presented compounds can become important materials in antimycobacterial research.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a aminoacyl-tRNA-synthetasy $7 D000604
- 650 _2
- $a antibakteriální látky $x farmakologie $7 D000900
- 650 12
- $a antiinfekční látky $x farmakologie $7 D000890
- 650 _2
- $a antituberkulotika $x farmakologie $7 D000995
- 650 _2
- $a houby $7 D005658
- 650 _2
- $a mikrobiální testy citlivosti $7 D008826
- 650 _2
- $a simulace molekulového dockingu $7 D062105
- 650 12
- $a Mycobacterium tuberculosis $7 D009169
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 650 _2
- $a amidy $x chemie $x farmakologie $7 D000577
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Needle, Adam Anthony $u Department of Pharmaceutical Chemistry and Pharmaceutical Analysis, Faculty of Pharmacy in Hradec Králové, Charles University, 500 05 Hradec Králové, Czech Republic
- 700 1_
- $a Jand'ourek, Ondřej $u Department of Biological and Medical Sciences, Faculty of Pharmacy in Hradec Králové, Charles University, 500 05 Hradec Králové, Czech Republic $1 https://orcid.org/0000000346332062 $7 xx0230412
- 700 1_
- $a Paterová, Pavla $u Department of Clinical Microbiology, University Hospital, 500 05 Hradec Králové, Czech Republic $1 https://orcid.org/0000000301927345 $7 xx0138094
- 700 1_
- $a Konečná, Klára $u Department of Biological and Medical Sciences, Faculty of Pharmacy in Hradec Králové, Charles University, 500 05 Hradec Králové, Czech Republic $1 https://orcid.org/0000000156707767 $7 uk20201094799
- 700 1_
- $a Bárta, Pavel $u Department of Biophysics and Physical Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, 500 05 Hradec Králové, Czech Republic $1 https://orcid.org/0000000154455658 $7 uk20211104475
- 700 1_
- $a Kuneš, Jiří $u Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, 500 05 Hradec Králové, Czech Republic
- 700 1_
- $a Kubíček, Vladimír $u Department of Biophysics and Physical Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, 500 05 Hradec Králové, Czech Republic
- 700 1_
- $a Doležal, Martin $u Department of Pharmaceutical Chemistry and Pharmaceutical Analysis, Faculty of Pharmacy in Hradec Králové, Charles University, 500 05 Hradec Králové, Czech Republic $1 https://orcid.org/0000000315586625 $7 jn19981000714
- 700 1_
- $a Kučerová-Chlupáčová, Marta $u Department of Pharmaceutical Chemistry and Pharmaceutical Analysis, Faculty of Pharmacy in Hradec Králové, Charles University, 500 05 Hradec Králové, Czech Republic $1 https://orcid.org/0000000286560740 $7 uk20201095433
- 773 0_
- $w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 24, č. 3 (2023)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36769275 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230418 $b ABA008
- 991 __
- $a 20250305132206 $b ABA008
- 999 __
- $a ok $b bmc $g 1924746 $s 1190469
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 24 $c 3 $e 20230202 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
- LZP __
- $a Pubmed-20230418